The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients

Leuk Res. 2013 Aug;37(8):883-8. doi: 10.1016/j.leukres.2013.04.020. Epub 2013 May 14.

Abstract

We evaluate the haematopathologic features of systemic mastocytosis associated with acute myeloid leukaemia (SM-AML) and the prognostic role of c-KIT mutation. Total 11 patients were enrolled. Cytochemistry using toluidine blue and tryptase was positive, as was immunohistochemistry for CD117 and CD25 on clustered mast cells; however, CD2 was expressed in only nine cases. In 10 cases, RUNX1-RUNX1T1 fusion gene was detected, and one patient presented with a t(5;6)(q22;q23) translocation at diagnosis. The c-KIT mutation D816V was detected in six patients. Patients with c-KIT mutations had higher relapse and death rates than those without; 4/5 (80.0%) and 5/6 (83.3%) vs. 1/5 (20%) and 2/5 (40%), respectively. Overall survival was also significantly shorter in cases with, than those without, c-KIT mutations. To identify rare cases of SM-AML, which have a dismal prognosis, c-KIT mutation study and careful examination for the presence of clustered mast cell infiltration by immunochemistry should be performed.

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • CD2 Antigens / metabolism
  • Child
  • Chromosomes, Human, Pair 5 / genetics
  • Chromosomes, Human, Pair 6 / genetics
  • Core Binding Factor Alpha 2 Subunit
  • Female
  • Humans
  • Immunohistochemistry
  • Leukemia, Myeloid / complications
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / genetics*
  • Male
  • Mast Cells / drug effects
  • Mast Cells / metabolism
  • Mast Cells / pathology
  • Mastocytosis, Systemic / complications
  • Mastocytosis, Systemic / drug therapy
  • Mastocytosis, Systemic / genetics*
  • Middle Aged
  • Mutation*
  • Oncogene Proteins, Fusion
  • Prognosis
  • Proto-Oncogene Proteins c-kit / genetics*
  • Proto-Oncogene Proteins c-kit / metabolism
  • RUNX1 Translocation Partner 1 Protein
  • Recurrence
  • Survival Analysis
  • Translocation, Genetic
  • Treatment Outcome
  • Young Adult

Substances

  • AML1-ETO fusion protein, human
  • CD2 Antigens
  • Core Binding Factor Alpha 2 Subunit
  • Oncogene Proteins, Fusion
  • RUNX1 Translocation Partner 1 Protein
  • Proto-Oncogene Proteins c-kit